No difference in OS between patients with advanced RET-rearranged lung cancers who received immunotherapy (n = 16) and those who did not receive immunotherapy (n = 46), (hazard ratio, 1.4 [95% CI, 0.7 to 2.9]; log-rank P = .35) (Table 4). This evidence concerns the gene RET and lung carcinoma.